Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bayer Aktienges Ads (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 64,566,300
  • Shares Outstanding, K 3,730,000
  • Annual Sales, $ 46,752 M
  • Annual Income, $ 2,002 M
  • 60-Month Beta 0.95
  • Price/Sales 1.42
  • Price/Cash Flow 6.71
  • Price/Book 1.14
  • Price/Earnings ttm 9.86
  • Earnings Per Share ttm 1.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/02/19
  • Annual Dividend & Yield 0.57 (3.29%)
  • Most Recent Dividend 0.569 on 05/25/18
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.47
  • Number of Estimates 1
  • High Estimate 0.47
  • Low Estimate 0.47
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -31.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.5900 +0.27%
on 03/22/19
20.6900 -19.60%
on 03/06/19
-2.2750 (-12.03%)
since 02/22/19
3-Month
16.5800 +0.33%
on 12/27/18
20.6900 -19.60%
on 03/06/19
-0.5550 (-3.23%)
since 12/21/18
52-Week
16.5800 +0.33%
on 12/27/18
32.8000 -49.28%
on 06/19/18
-11.7750 (-41.45%)
since 03/22/18

Most Recent Stories

More News
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

BAYRY : 16.6350 (-3.90%)
REGN : 391.80 (-2.68%)
AMGN : 186.70 (-2.70%)
SNY : 44.26 (-2.58%)
Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%

Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products(TM)" today announced it has received tentative approval from the U.S. Food and Drug Administration...

BAYRY : 16.6350 (-3.90%)
PRGO : 47.25 (-2.74%)
What Makes Bayer (BAYRY) a New Strong Buy Stock

Bayer (BAYRY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BAYRY : 16.6350 (-3.90%)
AstraZeneca Up This Year on New Drugs & Pipeline Progress

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

BAYRY : 16.6350 (-3.90%)
CELG : 88.15 (-1.65%)
AZN : 42.59 (-0.84%)
MRK : 82.29 (-0.80%)
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

BAYRY : 16.6350 (-3.90%)
AVEO : 0.58 (-6.65%)
CELG : 88.15 (-1.65%)
AZN : 42.59 (-0.84%)
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

BAYRY : 16.6350 (-3.90%)
AZN : 42.59 (-0.84%)
MRK : 82.29 (-0.80%)
BMY : 48.16 (-1.55%)
Should Value Investors Buy Bayer (BAYRY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BAYRY : 16.6350 (-3.90%)
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

BAYRY : 16.6350 (-3.90%)
CELG : 88.15 (-1.65%)
REGN : 391.80 (-2.68%)
SNY : 44.26 (-2.58%)
Microencapsulated Pesticides Market to Reach US$ 797.09 Mn by 2026 due to Rising Initiatives for Lowering Soil Pollution - TMR

The analysts at Transparency Market Research (TMR) estimates that the global microencapsulated pesticides market has a consolidative vendor landscape. The key players such as Syngenta, BASF SE, Bayer AG,...

BAYRY : 16.6350 (-3.90%)
BASFY : 18.4300 (-3.66%)
FMC : 74.98 (-3.39%)
Bayer Submits Application in EU for Prostate Cancer Drug

Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.

BAYRY : 16.6350 (-3.90%)
AZN : 42.59 (-0.84%)
JNJ : 136.91 (-0.86%)
BMY : 48.16 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade BAYRY with:

Key Turning Points

2nd Resistance Point 17.2583
1st Resistance Point 16.9467
Last Price 16.6350
1st Support Level 16.4567
2nd Support Level 16.2783

See More

52-Week High 32.8000
Fibonacci 61.8% 26.6040
Fibonacci 50% 24.6900
Fibonacci 38.2% 22.7760
Last Price 16.6350
52-Week Low 16.5800

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar